Brea C. Lipe, MD explains the trial design and patient population of PERSEUS phase three trial.
Summary
Brea C. Lipe, MD reviews the PERSEUS trial conducted by the European Myeloma Network. This trial was a phase three randomized trial of over 700 patients comparing a quadruplet regimen of lenalidomide, bortezomib, dexamethasone, and subcutaneous daratumumab (DARA) to a triplet without daratumumab (VRd) for 28-day cycles. After induction, patients went on to maintenance with lenalidomide and dexamethasone. Notably, patients in the Dara-VRd arm who were MRD negative for 12 consecutive months after 2 years maintenance were able to discontinue treatment. The trial demonstrated improved progression-free and overall survival with Dara-VRd compared to VRd. Recognizing these nuanced design and regimen details is important when interpreting the trial results and determining applicability.
Summary was AI-generated and edited for clarity.
Khouri Discusses Selinexor Dosing and Management Approaches for R/R MM
July 22nd 2024During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.
Read More
New Hope for Multiple Myeloma: Cilta-Cel Improves Overall Survival
July 2nd 2024The CARTITUDE-4 study that found that treatment with cilta-cel led to a statistically significant and clinically meaningful improvement in overall survival among patients with relapsed and lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.
Read More